Information Provided By: 
Fly News Breaks for June 9, 2016
ETRM
Jun 9, 2016 | 08:51 EDT
Roth Capital analyst Chris Lewis downgraded EnteroMedics to Neutral from Buy, saying that while he believes the company's vBloc therapy can still become a viable tool within the obesity treatment paradigm over the longer-term, he is scaling back his utilization assumptions over the coming years as EnteroMedics works towards securing expanded reimbursement. Lewis lowered his price target on the shares to 50c from $3.
News For ETRM From the Last 2 Days
There are no results for your query ETRM
